On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
-
BUSINESS Daiichi Sankyo to Harness Ties with Cardiologists in Lixiana Promotion
December 8, 2014
-
BUSINESS Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
-
REGULATORY ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
-
REGULATORY Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
December 3, 2014
-
BUSINESS Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
-
BUSINESS Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
-
BUSINESS A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
-
REGULATORY PAFSC’s Second Committee Backs Approval of Novartis’s Secukinumab
December 1, 2014
-
BUSINESS EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
-
INTERVIEW Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.
November 28, 2014
-
ACADEMIA Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official
November 27, 2014
-
BUSINESS Kaken Banking on Clenafin to Boost Dermatology Biz
November 27, 2014
-
REGULATORY Debates on Yearly NHI Price Cuts Put on Hold as Attention Turns to Election
November 26, 2014
-
REGULATORY PAFSC First Committee Backs Approval of Takeda’s Vonoprazan
November 25, 2014
-
ORGANIZATION JPMA President Opposes Annual NHI Price Revision
November 21, 2014
-
REGULATORY Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
-
REGULATORY 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
-
REGULATORY Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
-
REGULATORY PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations
November 17, 2014
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…